754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
David R. Spigel(Sarah Cannon), Heidi H. Gillenwater(Lyell Immunopharma (United States)), Hemant S. Murthy(University of Florida), Hirva Mamdani(Wayne State University), Jennifer M. Specht(University of Washington), Mary Lessig(Lyell Immunopharma (United States)), Sarah Fitzsimmons(Lyell Immunopharma (United States)), Saranya Chumsri(Jacksonville College), Lubna N. Chaudhary(Medical College of Wisconsin), Usama Gergis(Thomas Jefferson University Hospital), Babar Bashir(Thomas Jefferson University), Haven R. Garber(The University of Texas MD Anderson Cancer Center), Yazan Migdady(University of Florida), Chul Kim(Georgetown University), Yeonhee Kim(Lyell Immunopharma (United States)), Bishwa J Ganguly(Lyell Immunopharma (United States)), Erika Hamilton(Sarah Cannon), H.R. Jensen(Lyell Immunopharma (United States)), Hajime Hiraragi(Lyell Immunopharma (United States))
Cited by 4
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k
HER2-Low Breast Cancer: Pathological and Clinical Landscape
|Journal of Clinical Oncology|2020|801